FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Steven Waggoner

Research Profile

Disorders

Concepts & Ideas

Procedures

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Natalie Gould; Robert S Mannel; Michael W Sill; Premal H Thaker; Steven E Waggoner; Deborah K Armstrong; Paul A DiSilvestro; Paula M Fracasso; S Diane Yamada; Joan L Walker
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Vivian E von Gruenigen; Robert L DeBernardo; Susan M Eaton; Heidi E Frasure; Nancy L Fusco; Anne M Heugel; Deborah A Smith; Steven E Waggoner
Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study.
Samith Sandadi; Meredith J Broderick; Heidi E Frasure; Jacqualin A Miller; Steven E Waggoner; Vivian E von Gruenigen
The effect of sleep disturbance on quality of life in women with ovarian cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Steven Waggoner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Natalie Gould; Robert S Mannel; Michael W Sill; Premal H Thaker; Steven E Waggoner; Deborah K Armstrong; Paul A DiSilvestro; Paula M Fracasso; S Diane Yamada; Joan L Walker
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gynecologic oncology 2012;127(3):506-10.
2012: Vivian E von Gruenigen; Robert L DeBernardo; Susan M Eaton; Heidi E Frasure; Nancy L Fusco; Anne M Heugel; Deborah A Smith; Steven E Waggoner
Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study.
Anti-cancer drugs 2012;23(7):724-30.
2011: Samith Sandadi; Meredith J Broderick; Heidi E Frasure; Jacqualin A Miller; Steven E Waggoner; Vivian E von Gruenigen
The effect of sleep disturbance on quality of life in women with ovarian cancer.
Gynecologic oncology 2011;123(2):351-5.
2011: Mark A Morgan; Michael W Sill; Keiichi Fujiwara; Benjamin E Greer; Stephen C Rubin; Koen DeGeest; S Diane Yamada; Steven E Waggoner; Robert L Coleman; Joan L Walker; Robert S Mannel
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
Gynecologic oncology 2011;121(2):264-8.
2011: Charles A Kunos; Michael W Sill; Thomas E Buekers; Joan L Walker; Jeanne M Schilder; S Diane Yamada; Steven E Waggoner; Mohammed Mohiuddin; Paula M Fracasso
Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.
Gynecologic oncology 2011;120(2):224-8.
2009: David S Miller; John A Blessing; Carolyn N Krasner; Robert S Mannel; Parviz Hanjani; Michael L Pearl; Steven E Waggoner; Cecelia H Boardman
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(16):2686-91.
2005: Maryann Schroder; Loren K Mell; Jean A Hurteau; Yvonne Collins; Jacob Rotmensch; Steven E Waggoner; S Diane Yamada; William Small; Arno J Mundt
Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients.
International journal of radiation oncology, biology, physics 2005;61(4):1078-86.
2005: Franco M Muggia; John A Blessing; Steven E Waggoner; Jonathan S Berek; Bradley J Monk; Joel I Sorosky; Michael L Pearl
Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study.
Gynecologic oncology 2005;96(1):108-11.
2005: David S Miller; John A Blessing; Steven E Waggoner; Jeanne M Schilder; Joel I Sorosky; Jeffrey Bloss; Russell Schilder
Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
Gynecologic oncology 2005;96(1):67-71.
2004: Arno J Mundt; Jacob Rotmensch; Steven E Waggoner; S Diane Yamada; Gini F Fleming
Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies.
Gynecologic oncology 2004;92(3):801-5.
2003: David H Moore; James Donnelly; William P McGuire; Lois Almadrones; David Cella; Thomas J Herzog; Steven E Waggoner
Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(22):4207-13.
2003: Paula M Fracasso; John A Blessing; Judith Wolf; Thomas F Rocereto; Jonathan S Berek; Steven E Waggoner
Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Gynecologic oncology 2003;90(1):177-80.
2002: David S Miller; John A Blessing; Samuel S Lentz; Steven E Waggoner
A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.
Gynecologic oncology 2002;87(3):247-51.
2002: Arno J Mundt; Anthony E Lujan; Jacob Rotmensch; Steven E Waggoner; S Diane Yamada; Gini Fleming; John C Roeske
Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies.
International journal of radiation oncology, biology, physics 2002;52(5):1330-7.
2001: C Phelan; Anthony G Montag; Jacob Rotmensch; Steven E Waggoner; S Diane Yamada; Arno J Mundt
Outcome and management of pathological stage I endometrial carcinoma patients with involvement of the lower uterine segment.
Gynecologic oncology 2001;83(3):513-7.
2001: Arno J Mundt; John C Roeske; Anthony E Lujan; S Diane Yamada; Steven E Waggoner; Gini Fleming; Jacob Rotmensch
Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies.
Gynecologic oncology 2001;82(3):456-63.
2001: J B Ashman; Philip P Connell; D Yamada; Jacob Rotmensch; Steven E Waggoner; Arno J Mundt
Outcome of endometrial carcinoma patients with involvement of the uterine serosa.
Gynecologic oncology 2001;82(2):338-43.
2001: Arno J Mundt; Jacob Rotmensch; Steven E Waggoner; D Yamada; C Langhauser; Gini F Fleming
Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies.
Gynecologic oncology 2001;82(2):333-7.
2001: Arno J Mundt; Kevin T Murphy; Jacob Rotmensch; Steven E Waggoner; S Diane Yamada; Philip P Connell
Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma.
International journal of radiation oncology, biology, physics 2001;50(5):1154-60.
2001: Arno J Mundt; Russell McBride; Jacob Rotmensch; Steven E Waggoner; S Diane Yamada; Philip P Connell
Significant pelvic recurrence in high-risk pathologic stage I--IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy.
International journal of radiation oncology, biology, physics 2001;50(5):1145-53.
2001: Gini F Fleming; Jeffrey M Fowler; Steven E Waggoner; Larry J Copeland; Benjamin E Greer; Ira R Horowitz; G Sutton; Russell J Schilder; Paula M Fracasso; H G Ball; William P McGuire
Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1021-9.
2001: Gini F Fleming; Steven E Waggoner; Jacob Rotmensch; C Langhauser
Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel.
American journal of clinical oncology 2001;24(1):52-7.
2000: John C Roeske; Anthony E Lujan; Jacob Rotmensch; Steven E Waggoner; D Yamada; Arno J Mundt
Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies.
International journal of radiation oncology, biology, physics 2000;48(5):1613-21.
2000: I M Castro; Philip P Connell; Steven E Waggoner; Jacob Rotmensch; Arno J Mundt
Synchronous ovarian and endometrial malignancies.
American journal of clinical oncology 2000;23(5):521-5.
2000: B N Tran; Philip P Connell; Steven E Waggoner; Jacob Rotmensch; Arno J Mundt
Characteristics and outcome of endometrial carcinoma patients age 45 years and younger.
American journal of clinical oncology 2000;23(5):476-80.
2000: Arno J Mundt; Steven E Waggoner; D Yamada; Jacob Rotmensch; Philip P Connell
Age as a prognostic factor for recurrence in patients with endometrial carcinoma.
Gynecologic oncology 2000;79(1):79-85.
2000: Peter G Rose; M Rodriguez; Steven E Waggoner; Benjamin E Greer; Ira R Horowitz; Jeffrey M Fowler; William P McGuire
Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(16):2957-62.
2000: Jacob Rotmensch; Philip P Connell; D Yamada; Steven E Waggoner; Arno J Mundt
One versus two intracavitary brachytherapy applications in early-stage cervical cancer patients undergoing definitive radiation therapy.
Gynecologic oncology 2000;78(1):32-8.
2000: K Wollschlaeger; Philip P Connell; Steven E Waggoner; Jacob Rotmensch; Arno J Mundt
Acute problems during low-dose-rate intracavitary brachytherapy for cervical carcinoma.
Gynecologic oncology 2000;76(1):67-72.
1999: Philip P Connell; Jacob Rotmensch; Steven E Waggoner; Arno J Mundt
Race and clinical outcome in endometrial carcinoma.
Obstetrics and gynecology 1999;94(5 Pt 1):713-20.
1999: Douglas P Calvin; Philip P Connell; Jacob Rotmensch; Steven E Waggoner; Arno J Mundt
Surgery and postoperative radiation therapy in stage II endometrial carcinoma.
American journal of clinical oncology 1999;22(4):338-43.
1999: Philip P Connell; Jacob Rotmensch; Steven E Waggoner; Arno J Mundt
The significance of adnexal involvement in endometrial carcinoma.
Gynecologic oncology 1999;74(1):74-9.
1999: M F Weiss; Philip P Connell; Steven E Waggoner; Jacob Rotmensch; Arno J Mundt
External pelvic radiation therapy in stage IC endometrial carcinoma.
Obstetrics and gynecology 1999;93(4):599-602.
1999: Arno J Mundt; Steven E Waggoner; A Herbst; Jacob Rotmensch
Preoperative intracavitary brachytherapy in early-stage cervical carcinoma.
American journal of clinical oncology 1999;22(1):73-7.
1999: Arno J Mundt; Jacob Rotmensch; Steven E Waggoner; C Quiet; Gini Fleming
Phase I trial of concomitant chemoradiotherapy for cervical cancer and other advanced pelvic malignancies.
Gynecologic oncology 1999;72(1):45-50.
1998: P A Mitchell; Steven E Waggoner; Jacob Rotmensch; Arno J Mundt
Cervical cancer in the elderly treated with radiation therapy.
Gynecologic oncology 1998;71(2):291-8.
1998: Arno J Mundt; Philip P Connell; T Campbell; J H Hwang; Jacob Rotmensch; Steven E Waggoner
Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy.
Gynecologic oncology 1998;71(2):151-8.
1998: Steven E Waggoner; DA Baunoch; S A Anderson; F Leigh; V G Zagaja
Bcl-2 protein expression associated with resistance to apoptosis in clear cell adenocarcinomas of the vagina and cervix expressing wild-type p53.
Annals of surgical oncology 1998;5(6):544-7.
1998: Peter G Rose; John A Blessing; Linda Van Le; Steven E Waggoner
Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Gynecologic oncology 1998;70(2):263-6.
1997: Gini F Fleming; Steven E Waggoner; Jacob Rotmensch; L A Skoog; C Langhauser
Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer.
Gynecologic oncology 1997;65(1):42-5.
1997: John C Roeske; Arno J Mundt; Howard J Halpern; Patrick J Sweeney; Harold Sutton; C Powers; Jacob Rotmensch; Steven E Waggoner; Ralph R Weichselbaum
Late rectal sequelae following definitive radiation therapy for carcinoma of the uterine cervix: a dosimetric analysis.
International journal of radiation oncology, biology, physics 1997;37(2):351-8.
1996: Valerie Lindgren; Steven E Waggoner; Jacob Rotmensch
Monosomy 22 in two ovarian granulosa cell tumors.
Cancer genetics and cytogenetics 1996;89(2):93-7.
1996: Steven E Waggoner; S M Anderson; M C Luce; H Takahashi; J Boyd
p53 protein expression and gene analysis in clear cell adenocarcinoma of the vagina and cervix.
Gynecologic oncology 1996;60(3):339-44.
1996: J Boyd; H Takahashi; Steven E Waggoner; L A Jones; R A Hajek; J T Wharton; F S Liu; T Fujino; J C Barrett; john alan mclachlan
Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero.
Cancer 1996;77(3):507-13.
1995: LC Drinkard; Steven E Waggoner; R N Stein; R A Byrne; Richard A Larson
Acute myelomonocytic leukemia with abnormal eosinophils presenting as an ovarian mass: a report of two cases and a review of the literature.
Gynecologic oncology 1995;56(2):307-11.
1994: Steven E Waggoner; Robert Mittendorf; N Biney; D Anderson; Andreas Herbst
Influence of in utero diethylstilbestrol exposure on the prognosis and biologic behavior of vaginal clear-cell adenocarcinoma.
Gynecologic oncology 1994;55(2):238-44.
1994: Steven E Waggoner; X Wang
Effect of nicotine on proliferation of normal, malignant, and human papillomavirus-transformed human cervical cells.
Gynecologic oncology 1994;55(1):91-5.
1994: Steven E Waggoner; S M Anderson; S Van Eyck; J Fuller; M C Luce; Andreas Herbst
Human papillomavirus detection and p53 expression in clear-cell adenocarcinoma of the vagina and cervix.
Obstetrics and gynecology 1994;84(3):404-8.
1994: Jacob Rotmensch; Steven E Waggoner; C Quiet
Ultrasound guidance for placement of difficult intracavitary implants.
Gynecologic oncology 1994;54(2):159-62.